35. Pemphigus Clinical trials / Disease details
Clinical trials : 98 / Drugs : 126 - (DrugBank : 41) / Drug target genes : 23 - Drug target pathways : 168
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04422912 (ClinicalTrials.gov) | September 29, 2020 | 2/6/2020 | Open-label Study to Determine the Maximum Tolerated Dose of DSG3-CAART in Mucosal-dominant PV Patients (mPV) | A Phase 1, Open-label, Safety and Dosing Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in Subjects With Active, Anti-DSG3, Mucosal-dominant Pemphigus Vulgaris | Mucosal -Dominant Pemphigus Vulgaris | Biological: DSG3-CAART | Cabaletta Bio | NULL | Recruiting | 18 Years | N/A | All | 30 | Phase 1 | United States |